Lek, a Sandoz company, receives its 14th TOP 10 Education Management Award

  • In 2015, Lek, a Sandoz company, provided more than 229 thousand hours of education and training attended by all employees to a various degree.
  • Despite the challenging economic and financial climate, Lek has increased its funds for the education and development of employees in 2015 by more than 40% compared to 2014.
  • As part of an international pharmaceutical company, Lek has a considerable advantage in the education and training of its associates, including access to a broad spectrum of knowledge, various forms of education, and the opportunity to take part in international projects.
20. 10. 2016

Lek Pharmaceuticals, a Sandoz company, received the TOP 10 Education Management Award 2016 for the 14th time in a row, ranking itself once again among the ten best custodians of knowledge in Slovenia. The award has been presented by Planet GV and the Education Management Institute Sofos to ten companies in Slovenia which in the previous year invested the most intensely and systematically in the education of their employees.

In 2015, Lek, a Sandoz company, provided more than 229 thousand hours of education and training. Most training and education was focused on quality management, business skills and statutory and mandatory education. 

On average, Lek employees had 5.84 days of training in 2015, and a total of 8.93 days during the year including compulsory education in the workplace, which is 14% more than in 2014. Lek has increased the scope of funds dedicated to the education and development of the employees in 2015, despite the challenging economic and financial climate, by more than 40% compared to 2014. 

»We are aware that the future of our business depends on our employees and continuous development of their talents. Educational needs arise from individual needs related to a development plan of an individual associate, and business needs related to the organisation’s business strategy. When planning and introducing education programs we leverage synergies and advantages which we can offer to our employees as a part of the Novartis global system. Within the Group we have access to a wide range of knowledge and different forms of education,« explained Fikret Bašanović, Learning & Training manager at Lek, a Sandoz Company.

The main focus of education and training in 2015: Developing team work through our values

»In 2015, special attention was paid to the implementation of »Team building« programs that had a common denominator – the renewed Novartis values: innovation, quality, collaboration, performance, courage and integrity.

They were carried out under the title: „Developing team work through our values“. The participants strengthened the team ties through the company’s values. The team analised how to integrate the renewed values into their existing work and which areas still have space for improvements. The workshop consisted of a series of team exercises through which the participants elaborated the concept of values and the importance thereof, both for the company and each individual associate.

Through these values, the participants gave meaning to their daily work and analysed the areas in which values could be even more integrated in their work. In this way, the values became part of each individual and strengthened ties between the team members as well as ties between the teams within the company as a whole,« added Fikret Bašanović.   

* * *

Lek, a Sandoz company, is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit www.lek.si.

Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global (link is external).
For further details visit www.sandoz.com/makingaccesshappen

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications 
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32